- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT00554333
Comparative Study of Immunogenicity and Safety of Flu-ID Vaccine Versus Flu-IM Vaccine
An Open-label, Multi-centre, Randomised, Comparative Study of the Immunogenicity and Safety of an Inactivated Split-Virion Influenza Vaccine Administered by Intradermal Route (Flu-ID 15μg) Versus an Inactivated Adjuvanted Influenza Vaccine Administered by Intramuscular Route in Subjects 65 Years of Age or Older
Primary objective:
* Immunogenicity To demonstrate that the influenza vaccine administered by intradermal route at least as immunogenic as the adjuvanted influenza vaccine administered by intramuscular route at the same dosage in term of HA antibody titres
Secondary objectives
Immunogenicity
- To describe the immune response 21 days after vaccination with the influenza vaccine administered by ID route versus the adjuvanted influenza vaccine administered by IM route..
- To describe the compliance of both vaccines administered with the European Medicine Agency (EMEA) Note for Guidance immunogenicity criteria, specific for elderly subjects
Safety
- To describe the safety profile after vaccination in each group
Acceptability
- To describe the pain at the injection site
- To describe the comfort of the injection
Studie Overzicht
Toestand
Conditie
Interventie / Behandeling
Studietype
Inschrijving (Werkelijk)
Fase
- Fase 3
Contacten en locaties
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
- Aged 65 years or older on the day of inclusion
Exclusion Criteria:
- Febrile illness (oral temperature ≥37.5°C) on the day of inclusion
- Thrombocytopenia or bleeding disorder contraindicating intramuscular vaccination
- Unstable chronic illness
- Congenital or acquired immunodeficiency,
- Any blood or blood-derived product in the past 3 months
- Current abuse of alcohol or drug addiction
- Any vaccination in the past 4 weeks or planned in the 4 weeks following study vaccination
- Any vaccination against influenza in the past 6 months
- Subjects who previously received a vaccination against influenza by intradermal route
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Preventie
- Toewijzing: Gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Geen (open label)
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
---|---|
Experimenteel: 1
Inactivated Split-Virion Influenza Vaccine for Intradermal Route
|
Inactivated Split-Virion Influenza Vaccine for Intradermal Route
|
Actieve vergelijker: 2
Inactivated adjuvanted Influenza Vaccine for Intramuscular Route
|
Inactivated adjuvanted Influenza Vaccine for Intramuscular Route
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Tijdsspanne |
---|---|
Immunogenicity Anti-Haemagglutinin (Anti-HA) antibody titres (1/dil) for the three strains obtained on Day 21 after vaccination.
Tijdsspanne: 21 days
|
21 days
|
Secundaire uitkomstmaten
Uitkomstmaat |
Tijdsspanne |
---|---|
Immunogenicity The derived endpoints will be: - Anti-HA individual titre ratios [Day 21 / Day 0]
Tijdsspanne: 21 days
|
21 days
|
Immunogenicity The derived endpoints will be: - Seroprotection status [anti-HA individual titre ≥40 (1/dil)] on Day 21
Tijdsspanne: 21 days
|
21 days
|
Seroconversion or significant increase status at Day 21:anti-HA individual post-vaccination titre ≥40 (1/dil) on D21 for subjects with a pre-vaccination anti-HA individual titre <10 (1/dil) on D0
Tijdsspanne: 21 days
|
21 days
|
Seroconversion or significant increase status at D21: ≥4-fold increase from pre- to post-vaccination anti-HA individual titre on D21 for subjects with a pre-vaccination anti-HA individual titre ≥10 (1/dil)
Tijdsspanne: 21 days
|
21 days
|
Occurrence, time to onset, number of days of occurrence, and intensity of solicited injection site adverse reactions and systemic adverse reactions occurring from D0 to D7 after vaccination
Tijdsspanne: 7 days
|
7 days
|
Occurrence of some solicited adverse reactions occurring from D0 to D3 after vaccination as defined by the EMEA Note for Guidance [CPMP/BWP/214/96]
Tijdsspanne: 3 days
|
3 days
|
Occurrence, nature (MedDRA PT), time to onset, duration, intensity, and relationship to vaccination (only for systemic adverse events) of unsolicited (spontaneously reported) adverse events (injection site and systemic) occurring from D0 to visit 2
Tijdsspanne: 21 days (plus or minus 3 days)
|
21 days (plus or minus 3 days)
|
Occurrence, nature (MedDRA PT), time to onset, duration, intensity, and relationship to vaccination (only for systemic adverse events) of serious adverse events occurring from D0 to visit 2
Tijdsspanne: 21 days (plus or minus 3 days)
|
21 days (plus or minus 3 days)
|
Intensity of pain at the time of injection evaluated just after vaccination on D0 using a Verbal Rating Scale
Tijdsspanne: 1 day (day of vaccination)
|
1 day (day of vaccination)
|
Answers to the Vaccination Comfort Questionnaire completed on D21
Tijdsspanne: 21 days
|
21 days
|
Medewerkers en onderzoekers
Sponsor
Publicaties en nuttige links
Studie record data
Bestudeer belangrijke data
Studie start
Primaire voltooiing (Werkelijk)
Studie voltooiing (Werkelijk)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Schatting)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- FID01C
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .
Klinische onderzoeken op Influenza
-
Gamaleya Research Institute of Epidemiology and...VoltooidGriep A | Influenza A-virusinfectie | Influenza-epidemie | Influenza H5N1Russische Federatie
-
Vanderbilt University Medical CenterHuman Vaccines ProjectVoltooidVaccin reactie | Influenza | Influenza, mens | Griep A | Influenza type B | Influenza A H3N2 | Influenza A H1N1Verenigde Staten
-
NPO PetrovaxVoltooidVaccin reactie | Influenza | Influenza, mens | Griep A | Acute luchtweginfectie | Influenza type B | Griep | Influenza A H3N2 | Influenza A H1N1 | Griep, mens | Influenza-epidemieRussische Federatie
-
Quidel CorporationVoltooidInfluenza A, Influenza BVerenigde Staten
-
Vaxine Pty LtdAustralian Respiratory and Sleep Medicine InstituteVoltooid
-
Ology BioservicesVoltooidInfluenza, vogelAustralië, Finland, Singapore, Spanje
-
Henry M. Jackson Foundation for the Advancement...National Institute of Allergy and Infectious Diseases (NIAID); Food and Drug... en andere medewerkersActief, niet wervendInfluenza | Influenza-achtige ziekte | Influenza vaccinsVerenigde Staten
-
AVIR Green Hills Biotechnology AGVoltooidInfluenza, vogelRussische Federatie
-
National Institute of Allergy and Infectious Diseases...Voltooid
-
National Institute of Allergy and Infectious Diseases...Voltooid
Klinische onderzoeken op Flu-ID 15μg
-
PepTcell LimitedVoltooid
-
University of California, San FranciscoAmerican Cancer Society, Inc.; Kaiser PermanenteVoltooid
-
Green Cross CorporationVoltooid
-
Eurocine Vaccines ABVoltooid
-
Queen's University, BelfastUniversity of Sheffield; University of Glasgow; University of South Wales; Baily...Werving
-
GlaxoSmithKlineVoltooid
-
Tatyana ZubkovaVoltooidInfecties met respiratoir syncytieel virusRussische Federatie
-
PulseMedicaWerving
-
PATHSID TechnologiesVoltooidInjecties, intradermaalVerenigde Staten
-
Aga Khan UniversityWorld Health OrganizationVoltooid